Drug Trial Radar · NCT07226791
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Feb 4, 2026
Primary completion
Sep 2028
Study completion May 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closing the belly wall after open ventral hernia surgery, without needing a complex procedure. Adverse Events and change in disease activity will be assessed. AGN-151607-DP is an investigational drug being developed to treat ventral hernia. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 200 adult participants with midline ventral hernia needing open surgical repair will be enrolled in approximately 30 sites in the United States. Participants will receive intramuscular injections of AGN-161607-DP or matching placebo on Day 1. Duration of the study is approximately 25 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Ventral Hernia
Interventions
AGN-151607-DPDrug
Intramuscular Injection
Placebo for AGN-151607-DPDrug
Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Primary Fascial Closure (PFC) Without Use of Component Separation Technique (CST) in Open Ventral Hernia Surgical RepairTime frame: Up to approximately 1 Month
- Percentage of Participants Experiencing Adverse EventsTime frame: Up to approximately 25 Months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
CARI Clinical Trials INC /ID# 278844
Riverside, California · Recruiting
University of Florida - Jacksonville /ID# 261992
Jacksonville, Florida · Completed
Medical Research Center /ID# 278680
Miami, Florida · Recruiting
Avanza Medical Research Center /ID# 278885
Pensacola, Florida · Recruiting
NorthShore University-Endeavor Health Evanston Hospital /ID# 277995
Evanston, Illinois · Recruiting
Integrity Clinical Research /ID# 278710
Wichita, Kansas · Completed
Mayo Clinic Hospital Rochester /ID# 278995
Rochester, Minnesota · Recruiting
Novant Health New Hanover Regional Medical Center /ID# 261979
Wilmington, North Carolina · Recruiting
Cleveland Clinic - Cleveland /ID# 277914
Cleveland, Ohio · Recruiting
Penn State Milton S. Hershey Medical Center /ID# 261987
Hershey, Pennsylvania · Recruiting
Prisma Health Greenville Memorial Hospital /ID# 261995
Greenville, South Carolina · Recruiting
Baylor University Medical Center /ID# 261955
Dallas, Texas · Recruiting
Carilion Roanoke Memorial Hospital /ID# 278577
Roanoke, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.